Platelets promote acute liver injury via extracellular vesicles-mediated Aldolase A

This study reveals that platelets exacerbate acute liver injury by delivering extracellular vesicle-mediated aldolase A to Kupffer cells, triggering a metabolic reprogramming that drives pro-inflammatory activation and identifying ALDOA as a promising therapeutic target and biomarker.

The Gist

The Big Picture: A Fire in the Liver

Imagine your liver is a busy city. When you take too much acetaminophen (like Tylenol), it's like someone accidentally drops a lit match in the city center. This starts a fire (liver injury).

Usually, the city's emergency response team (the immune system) rushes in to put out the fire. But in this study, the researchers discovered that a specific group of "first responders" (platelets) actually makes the fire worse. They don't just try to help; they accidentally hand the fire a bucket of gasoline.

The Cast of Characters

1. The Liver (The City): The organ that gets damaged.
2. Acetaminophen (The Match): The drug overdose that starts the trouble.
3. Kupffer Cells (The Firefighters): These are the liver's resident immune cells. Their job is to clean up debris and fight infection. In this story, they get confused and start fanning the flames instead of putting them out.
4. Platelets (The Messengers): Usually known for clotting blood to stop bleeding, these cells rush to the injured liver. The study found they are the ones handing the "gasoline" to the firefighters.
5. ALDOA (The Gasoline): A specific protein (an enzyme) that acts like fuel.
6. Extracellular Vesicles (The Delivery Trucks): Tiny bubbles released by platelets that act like delivery trucks, carrying the ALDOA fuel to the Kupffer cells.

The Story: How the Damage Happens

1. The Arrival of the Messengers
When the liver is injured by an overdose, platelets are the first to arrive. Think of them as the first police cars on the scene. Instead of just blocking traffic, they park next to the Kupffer cells (the firefighters) and start talking to them.

2. The Dangerous Delivery
The platelets release tiny "delivery trucks" called extracellular vesicles. Inside these trucks is a specific cargo: a protein called ALDOA.

• Analogy: Imagine the platelets are sending a text message to the firefighters, but instead of words, they send a package of high-octane rocket fuel.

3. The Metabolic Switch (The Gasoline Kick)
When the Kupffer cells receive these trucks, they open the package and find the ALDOA. This protein forces the cells to switch their energy source.

• The Switch: Normally, cells run on a slow, efficient battery (Oxidative Phosphorylation). The ALDOA forces them to switch to a "turbo mode" called Glycolysis.
• The Result: This turbo mode is fast but messy. It makes the Kupffer cells hyper-active and angry. Instead of cleaning up the injury, they start screaming inflammatory signals, causing massive collateral damage to the liver tissue. It's like the firefighters, now fueled by rocket fuel, start shooting water cannons so hard they break the building's walls.

4. The Proof
The researchers tested this theory in three ways:

• Removing the Messengers: They blocked the platelets. Without the platelets, the firefighters didn't get the "fuel," and the liver injury was much less severe.
• Removing the Fuel: They used a special drug (Aldometanib) to stop the ALDOA protein from working. Even with the platelets there, the firefighters couldn't get the "turbo boost," and the liver was saved.
• Human Connection: They looked at blood from real patients with acute liver injury. They found that patients with the most severe liver damage had the highest levels of this "fuel" (ALDOA) in their blood.

The Solution: A New Way to Treat Liver Failure

Currently, if someone overdoses on Tylenol, the only treatment is a drug called N-acetylcysteine (NAC), which has to be given very quickly (within hours) to stop the initial chemical reaction. If you miss that window, there isn't much else doctors can do.

This study suggests a new strategy:
Instead of just trying to stop the initial match (the overdose), we can stop the firefighters from getting the rocket fuel. By using a drug to block ALDOA, we can calm down the immune system and stop the liver from destroying itself, even if the treatment starts a bit later.

The Takeaway

This paper reveals a secret communication line between blood cells (platelets) and liver immune cells (Kupffer cells). The platelets send a protein (ALDOA) inside tiny bubbles that turns the liver's immune cells into a destructive force.

The Moral of the Story: Sometimes, the helpers (platelets) accidentally make the problem worse by giving the wrong tools (ALDOA) to the people trying to fix it. If we can stop the delivery of those tools, we can save the city (the liver).

This discovery offers a potential new "fire extinguisher" for acute liver injury that could work even after the initial damage has started.

Technical Summary

Title

Platelets promote acute liver injury via extracellular vesicles-mediated Aldolase A transfer to Kupffer cells.

1. Problem Statement

Acute Liver Injury (ALI), particularly induced by acetaminophen (APAP) overdose, is a life-threatening condition characterized by rapid hepatocyte death and sterile inflammation. While the role of hepatocytes and Kupffer cells (KCs, liver-resident macrophages) is recognized, the specific cellular drivers and molecular mechanisms initiating the inflammatory cascade remain incompletely defined.

• Clinical Observation: Patients with severe ALI often exhibit thrombocytopenia (low platelet counts), yet these "lost" platelets accumulate in the liver, suggesting a pathogenic role.
• Knowledge Gap: The mechanism by which platelets interact with KCs to exacerbate liver injury is unknown. Specifically, it is unclear if platelets induce metabolic reprogramming (the "Warburg effect") in KCs to drive inflammation.

2. Methodology

The study employed a multi-faceted approach combining in vivo mouse models, in vitro cell culture, omics technologies, and clinical sample analysis.

• Animal Models:
  • APAP-induced ALI: Wild-type (WT) C57BL/6J mice treated with APAP (210 mg/kg).
  • Genetic Manipulation: Generation of platelet-specific Aldoa knockout mice (PF4ΔAldoa) by crossing Aldoa^fl/fl mice with PF4-Cre transgenic mice.
  • Cell Depletion/Inhibition:
    • Platelet depletion via anti-CD41 antibody.
    • Kupffer cell depletion via clodronate liposomes (CLDN).
    • Glycolysis inhibition via 2-deoxy-D-glucose (2-DG).
    • Pharmacological inhibition of ALDOA using Aldometanib.
  • Rescue Experiments: Reconstitution of platelet-depleted mice with isolated Platelet-Derived Extracellular Vesicles (PEVs).
• Cellular & Molecular Techniques:
  • Isolation: Primary isolation of mouse platelets and Kupffer cells (via collagenase perfusion and density gradient centrifugation).
  • EV Characterization: Isolation of PEVs via ultracentrifugation; validation via TEM, Nanoparticle Tracking Analysis (NTA), and Western Blot (TSG101, CD63).
  • Metabolic Profiling: Seahorse XF Analyzer to measure Extracellular Acidification Rate (ECAR) and Oxygen Consumption Rate (OCR) in KCs.
  • Omics: RNA-seq of KCs (KEGG/GSVA analysis) and Mass Spectrometry (LC-MS/MS) of PEV proteome to identify cargo.
  • Clinical Correlation: Analysis of human serum samples from ALI patients and re-analysis of public proteomic datasets (platelet alpha-granules, Polycythemia Vera, Alzheimer's).

3. Key Contributions

1. Discovery of a Platelet-KC Metabolic Axis: Identified that recruited platelets drive a glycolytic switch in Kupffer cells, which is a critical driver of ALI.
2. Mechanism of Intercellular Communication: Demonstrated that platelets communicate with KCs via Extracellular Vesicles (EVs) rather than direct cell-cell contact or soluble cytokines alone.
3. Identification of ALDOA as the Effector: Pinpointed Aldolase A (ALDOA), a glycolytic enzyme, as the specific protein cargo within PEVs responsible for reprogramming KC metabolism.
4. Therapeutic Validation: Established that genetic ablation of Aldoa in platelets or pharmacological inhibition of ALDOA (using Aldometanib) significantly protects against liver injury, even when administered after the initial insult.
5. Clinical Relevance: Validated that circulating ALDOA levels correlate with disease severity in human ALI patients, proposing it as a biomarker and therapeutic target.

4. Key Results

• Platelets Drive Glycolysis in KCs:

  • APAP treatment leads to platelet infiltration and colocalization with KCs.
  • RNA-seq of KCs from APAP-injured mice showed upregulation of glycolysis genes (e.g., Slc2a1, Pfkfb3, Pkm) and downregulation of oxidative phosphorylation (Oxphos).
  • Depleting platelets in vivo or co-culturing KCs with platelets in vitro confirmed that platelets are necessary and sufficient to induce this glycolytic switch.

• PEVs are the Mediators:

  • Conditioned media from platelets induced glycolysis in KCs.
  • Isolated PEVs (59–288 nm) recapitulated this effect, increasing ECAR and inflammatory gene expression in KCs.
  • In vivo rescue experiments showed that injecting PEVs into platelet-depleted mice restored liver injury, confirming PEVs as the pathogenic vehicle.

• ALDOA is the Critical Cargo:

  • Proteomic analysis of PEVs identified 121 proteins; filtering against hepatocyte EVs and cytoskeletal/coagulation proteins left 7 candidates.
  • ALDOA was selected due to its role in glycolysis. Western blot confirmed high ALDOA levels in PEVs.
  • Treatment of KCs with recombinant ALDOA (rALDOA) alone was sufficient to increase glycolytic flux and inflammation.
  • Serum ALDOA levels rose rapidly (within 3h) post-APAP and were dependent on platelets (reduced in platelet-depleted mice).

• Therapeutic Efficacy:

  • Genetic: PF4ΔAldoa mice showed significantly reduced liver necrosis and ALT levels compared to controls after APAP challenge.
  • Pharmacological: Administration of Aldometanib (an ALDOA inhibitor) 1 hour after APAP overdose significantly attenuated liver injury. This protection was independent of APAP metabolism (CYP2E1/NAPQI levels unchanged).
  • Broad Applicability: Aldometanib also protected against Concanavalin A (Con A)-induced immune hepatitis, suggesting a broader role in ALI.

• Clinical Correlation:

  • ALDOA is present in human platelet alpha-granules.
  • In a cohort of ALI patients, circulating ALDOA levels showed a strong positive correlation with serum ALT (a marker of liver damage).

5. Significance

• Novel Pathogenesis: The study redefines the role of platelets in sterile inflammation, moving beyond hemostasis to active metabolic reprogramming of immune cells via EVs.
• Therapeutic Window: Unlike current standard therapies (e.g., N-acetylcysteine) which must be administered before or immediately after toxin exposure, targeting the ALDOA pathway protects against the secondary inflammatory wave. This offers a wider therapeutic window for treating established liver injury.
• Biomarker Potential: Circulating ALDOA serves as a potential prognostic biomarker for disease severity in ALI.
• Translational Impact: The findings nominate ALDOA as a druggable target, with existing inhibitors (Aldometanib) showing immediate potential for repurposing in acute liver failure scenarios.

Conclusion: The paper elucidates a specific pathway: Platelets → PEVs → ALDOA transfer → KC Glycolytic Switch → Inflammatory Amplification → Hepatocyte Necrosis. Targeting this axis offers a promising strategy for treating acute liver injury.